Cancer Letters, 69 (1993) 209–211
Elsevier Scientific Publishers Ireland Ltd.

Subject Index

Volume 69

aflatoxin B_1, methyl-deficient diet, rat liver, serum enzymes, necrosis, lipidosis, 93
alpha-antitrypsin, rat intestinal tumors, azoxymethane, chemoprevention, 39
amino acids alcohols, differentiation, growth inhibition, melanoma, 203
animal lectins, cell-cycle kinetics, gene expression, 67
anticancer effect, polyamine uptake, spermidine, spermine, ornithine decarboxylase, *S*-adenosylmethionine decarboxylase, α-difluoromethylornithine, L1210 leukemia, 33
antigen, sarcoma, purification, sarcoma antigen, 173
antisense, *neu*, oncogene, neuroblastoma, 27
autochthonous murine mammary tumors, MMTV, enterovirus, immune tolerance, cyclophosphamide, host control of cancer, 133
azoxymethane, alpha-antitrypsin, rat intestinal tumors, chemoPrevention, 39

basement membrane, invasion, human assay, extracellular matrix, 123
benzoyl peroxide, biomimetic superoxide dismutase, promotion, progression, skin tumors, 167
bile acids, deoxycholate, colon tumor cell differentiation, 181
biomimetic superoxide dismutase, benzoyl peroxide, promotion, progression, skin tumors, 167
bleomycin, electrotherapy, fibrosarcoma experimental, 81
breast cyst fluid, cathepsin D, pS2, oestradiol, 21

c-Ha-*ras*, oncogene product, protease inhibitor, cathepsin, 161
cancer risk assessment, pharmacokinetics, physiological models, metabolism, tissue binding, tissue reactivity, chemical carcinogenesis, pharmacodynamics, tissue dosimetry, sensitivity analysis, 1
carcinogenesis, green tea, catechins, tumor promotion, gap junctions, chemoprevention, 15
catechins, green tea, tumor promotion, carcinogenesis, gap junctions, chemoprevention, 15
cathepsin D, pS2, oestradiol, breast cyst fluid, 21
cathepsin, c-Ha-*ras*, oncogene product, protease inhibitor, 161
cell-cycle kinetics, animal lectins, gene expression, 67
chemical carcinogenesis, glutathione levels, *Saraka asoca*, (-)-epicatechin, 45
chemical carcinogenesis, pharmacokinetics, physiological models, metabolism, tissue binding, tissue reactivity, cancer risk assessment, pharmacodynamics, tissue dosimetry, sensitivity analysis, 1
chemoprevention, alpha-antitrypsin, rat intestinal tumors, azoxymethane, 39
chemoprevention, green tea, catechins, tumor promotion, carcinogenesis, gap junctions, 15
colon tumor cell differentiation, bile acids, deoxycholate, 181
colony formation, vinblastine, TN-16, renal carcinoma cells, soybean trypsin inhibitor, in vitro invasion assay, 85
cotinine, urine mutagenicity, tobacco habits, 75
cyclophosphamide, autochthonous murine mammary tumors, MMTV, enterovirus, immune tolerance, host control of cancer, 133
cyclosporin A, P-glycoprotein, *mdr* genes, natural killer cells, multiple drug resistance, 139
cytochrome*P*-450, methylbutylnitrosamine, nitrosamine, esophagus, liver microsomes, monoclonal antibody, 107
cytokines, heparin, transformation, soft agar, 197

deoxycholate, bile acids, colon tumor cell differentiation, 181
diagnostics of cancer, fluorescent dyes, induced tumors, human gastric cancer, 117
dietary fat, transgenic mice, oncogene amplification, hypomethylation, 59
differentiation, amino acids alcohols, growth inhibition, melanoma, 203
α-difluoromethylornithine, polyamine uptake, spermidine, spermine, ornithine decarboxylase, *S*-adenosylmethionine decarboxylase, L1210 leukemia, anticancer effect, 33

electrotherapy, bleomycin, fibrosarcoma experimental, 81
enterovirus, autochthonous murine mammary tumors, MMTV, immune tolerance, cyclophosphamide, host control of cancer, 133
(-)-epicatechin, chemical carcinogenesis, glutathione levels, *Saraka asoca*, 45
esophagus, methylbutylnitrosamine, nitrosamine, liver microsomes, cytochrome*P*-450, monoclonal antibody, 107
extracellular matrix, invasion, human assay, basement membrane, 123

fibrosarcoma experimental, bleomycin, electrotherapy, 81
fluorescent dyes, induced tumors, human gastric cancer, diagnostics of cancer, 117

gap junctions, green tea, catechins, tumor promotion, carcinogenesis, chemoprevention, 15
gene expression, animal lectins, cell-cycle kinetics, 67

glutathione levels, chemical carcinogenesis, *Saraka asoca*, (-)-epicatechin, 45
granulocyte-macrophage colony stimulating factor, transferrin, insulin, myeloid leukemia, receptor trafficking, hyperosmolar medium, 51
green tea, catechins, tumor promotion, carcinogenesis, gap junctions, chemoprevention, 15
growth inhibition, amino acids alcohols, differentiation, melanoma, 203

heparin, cytokines, transformation, soft agar, 197
host control of cancer, autochthonous murine mammary tumors, MMTV, enterovirus, immune tolerance, cyclophosphamide, 133
human assay, invasion, extracellular matrix, basement membrane, 123
human gastric cancer, fluorescent dyes, induced tumors, diagnostics of cancer, 117
hyperosmolar medium, transferrin, insulin, granulocyte-macrophage colony stimulating factor, myeloid leukemia, receptor trafficking, 51
hypomethylation, dietary fat, transgenic mice, oncogene amplification, 59

IM-9 cells, interleukin-2, polyphenols, Molt-4, 191
immune tolerance, autochthonous murine mammary tumors, MMTV, enterovirus, cyclophosphamide, host control of cancer, 133
immunohistochemistry, sequencing, p53, pancreatic cancer, 151
in vitro invasion assay, vinblastine, TN-16, renal carcinoma cells, soybean trypsin inhibitor, colony formation, 85
induced tumors, fluorescent dyes, human gastric cancer, diagnostics of cancer, 117
insulin, transferrin, granulocyte-macrophage colony stimulating factor, myeloid leukemia, receptor trafficking, hyperosmolar medium, 51
interleukin-2, polyphenols, Molt-4, IM-9 cells, 191
invasion, human assay, extracellular matrix, basement membrane, 123

L1210 leukemia, polyamine uptake, spermidine, spermine, ornithine decarboxylase, *S*-adenosylmethionine decarboxylase, α-difluoromethylornithine, anticancer effect, 33
lipidosis, aflatoxin B_1, methyl-deficient diet, rat liver, serum enzymes, necrosis, 93
liver microsomes, methylbutylnitrosamine, nitrosamine, esophagus, cytochrome*P*-450, monoclonal antibody, 107

mammary tumor, thymosin α_1, 187
mdr genes, P-glycoprotein, natural killer cells, multiple drug resistance, cyclosporin A, 139
melanoma, amino acids alcohols, differentiation, growth inhibition, 203
metabolism, pharmacokinetics, physiological models, tissue binding, tissue reactivity, chemical carcinogenesis, cancer risk assessment, pharmacodynamics, tissue dosimetry, sensitivity analysis, 1
methyl-deficient diet, aflatoxin B_1, rat liver, serum enzymes, necrosis, lipidosis, 93
methylbutylnitrosamine, nitrosamine, esophagus, liver microsomes, cytochrome*P*-450, monoclonal antibody, 107
MMTV, autochthonous murine mammary tumors, enterovirus, immune tolerance, cyclophosphamide, host control of cancer, 133
Molt-4, interleukin-2, polyphenols, IM-9 cells, 191
monoclonal antibody, methylbutylnitrosamine, nitrosamine, esophagus, liver microsomes, cytochrome*P*-450, 107
multiple drug resistance, P-glycoprotein, *mdr* genes, natural killer cells, cyclosporin A, 139
myeloid leukemia, transferrin, insulin, granulocyte-macrophage colony stimulating factor, receptor trafficking, hyperosmolar medium, 51

natural killer cells, P-glycoprotein, *mdr* genes, multiple drug resistance, cyclosporin A, 139
necrosis, aflatoxin B_1, methyl-deficient diet, rat liver, serum enzymes, lipidosis, 93
neu, antisense, oncogene, neuroblastoma, 27
neuroblastoma, *neu*, antisense, oncogene, 27
nitrosamine, methylbutylnitrosamine, esophagus, liver microsomes, cytochrome*P*-450, monoclonal antibody, 107

oestradiol, cathepsin D, pS2, breast cyst fluid, 21
oncogene amplification, dietary fat, transgenic mice, hypomethylation, 59
oncogene product, c-Ha-*ras*, protease inhibitor, cathepsin, 161
oncogene, *neu*, antisense, neuroblastoma, 27
ornithine decarboxylase, polyamine uptake, spermidine, spermine, *S*-adenosylmethionine decarboxylase, α-difluoromethylornithine, L1210 leukemia, anticancer effect, 33

P-glycoprotein, *mdr* genes, natural killer cells, multiple drug resistance, cyclosporin A, 139
p53, immunohistochemistry, sequencing, pancreatic cancer, 151
pancreatic cancer, immunohistochemistry, sequencing, p53, 151
pharmacodynamics, pharmacokinetics, physiological models, metabolism, tissue binding, tissue reactivity, chemical carcinogenesis, cancer risk assessment, tissue dosimetry, sensitivity analysis, 1
pharmacokinetics, physiological models, metabolism, tissue binding, tissue reactivity, chemical carcinogenesis, cancer risk assessment, pharmacodynamics, tissue dosimetry, sensitivity analysis, 1
physiological models, pharmacokinetics, metabolism, tissue binding, tissue reactivity, chemical carcinogenesis, cancer risk assessment, pharmacodynamics, tissue dosimetry, sensitivity analysis, 1
polyamine uptake, spermidine, spermine, ornithine decarboxylase, *S*-adenosylmethionine decarboxylase, α -difluoromethylornithine, L1210 leukemia, anticancer effect, 33
polyphenols, interleukin-2, Molt-4, IM-9 cells, 191
progression, benzoyl peroxide, biomimetic superoxide dismutase, promotion, skin tumors, 167

promotion, benzoyl peroxide, biomimetic superoxide dismutase, progression, skin tumors, 167
protease inhibitor, c-Ha-*ras*, oncogene product, cathepsin, 161
pS2, cathepsin D, oestradiol, breast cyst fluid, 21
purification, sarcoma, antigen, sarcoma antigen, 173

rat intestinal tumors, alpha-antitrypsin, azoxymethane, chemoprevention, 39
rat liver, aflatoxin B_1, methyl-deficient diet, serum enzymes, necrosis, lipidosis, 93
receptor trafficking, transferrin, insulin, granulocyte-macrophage colony stimulating factor, myeloid leukemia, hyperosmolar medium, 51
renal carcinoma cells, vinblastine, TN-16, soybean trypsin inhibitor, in vitro invasion assay, colony formation, 85

S-adenosylmethionine decarboxylase, polyamine uptake, spermidine, spermine, ornithine decarboxylase, α-difluoromethylornithine, L1210 leukemia, anticancer effect, 33
Saraka asoca, chemical carcinogenesis, glutathione levels, (-)-epicatechin, 45
sarcoma antigen, sarcoma, antigen, purification, 173
sarcoma, antigen, purification, sarcoma antigen, 173
sensitivity analysis, pharmacokinetics, physiological models, metabolism, tissue binding, tissue reactivity, chemical carcinogenesis, cancer risk assessment, pharmacodynamics, tissue dosimetry, 1
sequencing, immunohistochemistry, p53, pancreatic cancer, 151
serum enzymes, aflatoxin B_1, methyl-deficient diet, rat liver, necrosis, lipidosis, 93
skin tumors, benzoyl peroxide, biomimetic superoxide dismutase, promotion, progression, 167
soft agar, heparin, cytokines, transformation, 197
soybean trypsin inhibitor, vinblastine, TN-16, renal carcinoma cells, in vitro invasion assay, colony formation, 85
spermidine, polyamine uptake, spermine, ornithine decarboxylase, *S*-adenosylmethionine decarboxylase, α-difluoromethylornithine, L1210 leukemia, anticancer effect, 33
spermine, polyamine uptake, spermidine, ornithine decarboxylase, *S*-adenosylmethionine decarboxylase, α-difluoromethylornithine, L1210 leukemia, anticancer effect, 33

thymosin α_1, mammary tumor, 187
tissue binding, pharmacokinetics, physiological models, metabolism, tissue reactivity, chemical carcinogenesis, cancer risk assessment, pharmacodynamics, tissue dosimetry, sensitivity analysis, 1
tissue dosimetry, pharmacokinetics, physiological models, metabolism, tissue binding, tissue reactivity, chemical carcinogenesis, cancer risk assessment, pharmacodynamics, sensitivity analysis, 1
tissue reactivity, pharmacokinetics, physiological models, metabolism, tissue binding, chemical carcinogenesis, cancer risk assessment, pharmacodynamics, tissue dosimetry, sensitivity analysis, 1
TN-16, vinblastine, renal carcinoma cells, soybean trypsin inhibitor, in vitro invasion assay, colony formation, 85
tobacco habits, cotinine, urine mutagenicity, 75
transferrin, insulin, granulocyte-macrophage colony stimulating factor, myeloid leukemia, receptor trafficking, hyperosmolar medium, 51
transformation, heparin, cytokines, soft agar, 197
transgenic mice, dietary fat, oncogene amplification, hypomethylation, 59
tumor promotion, green tea, catechins, carcinogenesis, gap junctions, chemoprevention, 15

urine mutagenicity, cotinine, tobacco habits, 75

vinblastine, TN-16, renal carcinoma cells, soybean trypsin inhibitor, in vitro invasion assay, colony formation, 85

Cancer Letters, 69 (1993) 213–214
Elsevier Scientific Publishers Ireland Ltd.

Author Index
Volume 69

Akin, C. 51
Andersen, M.E. 1
Ask, A. 33
Askew, D. 67

Babcook, D.M. 107
Barsoum, A.L. 187
Beger, H.G. 151
Bhisey, R.A. 75
Biggs, M.W. 133
Braginskaja, O.V. 117
Buchler, M. 151
Burger, C.J. 67
Bynum, R.L. 197

Campbell, J.S. 93
Casey, G. 151
Chang, S.-H. 27
Chang, W.-C. 27
Chen, S.C. 107
Chiou, S.-T. 27
Cornell, C. 21

Das, N.P. 191
Desai, T.K. 181
Deutsch, A.A. 203
Devi, M.A. 191
Durán, H.A. 167

Eiselein, J.E. 133
Elgert, K.D. 67

Farmer, S.J. 59
Feit, C. 173
Friess, H. 151
Fujita-Yoshigaki, J. 161

Gekeler, V. 139
Gelboin, H.V. 107
Ghose, T. 39
Goodly, L.J. 123
Govekar, R.B. 75
Gupta, N.K. 173

Handgretinger, R. 139
Heby, O. 33
Hirshaut, Y. 173
Hiwasa, T. 161
Huang, Q. 107
Hurst, R.E. 197

Igawa, T. 85

Kanda, S. 85
Kanetake, H. 85
Kaufman, D.G. 123
Kawamura, M. 85
Kennedy, J.W. 123
Kobrin, M.S. 151
Koide, H. 161
Korc, M. 151
Krewski, D. 1
Kurl, R.N. 187

Lai, L.C. 21
Lai, M.-D. 27
Landau, O. 203
Lanfranchi, H. 167
Laver, G.W. 93
Lazarev, V.V. 117
Lennard, T.W.J. 21
Lopez, M.E. 151

Mehta, R. 93
Miklavcic, D. 81
Miller, Y. 123
Mirvish, S.S. 107
Morin, M.J. 181
Mueller, R. 93

Nair, S.C. 45
Nakamura, M. 85
Nathan, D.F. 181
Naylor, P.H. 187
Niethammer, D. 139
Noller, A. 139
Nordenberg, J. 203
Novakovic, S. 81
Novogrodsky, A. 203
Nüssler, V. 139

Palmieri, M.A. 167
Panet, H. 203
Panikkar, B. 45

Panikkar, K.R. 45
Park, S.S. 107
Perrson, L. 33
Polsachev, V.I. 117
Probst, H. 139

Reddy, B.S. 39
Reiss, R. 203
de Rey, B.M. 167
Rhodes, S.W. 197
Rijhsinghani, K. 39
Rinehart, C.A. 123
Rubin, L.B. 117
Ruch, R.J. 15

Saito, Y. 85
Sakiyama, S. 161
Sawada, T. 161
Schmall, B. 173
Seiler, N. 33
Sersa, G. 81
Shaw, Y.-T. 27
Shirouzu, M. 161
Siegal, G.P. 123
Sigler, K. 15
Singh, R.K. 123
Sonnenfeld, G. 51
Stapley, R. 93
Steinmeyer, C. 59
Stoskii, V.E. 117

Varghese, C.D. 45

Waddell, K. 59
Wang, M.-H. 123
Wang, S. 107
Wasserman, L. 203
Weger, S. 139
Wilisch, A. 139

De Wille, J.W. 59
Withey, J.R. 1

Yamanaka, Y. 151
Yokoyama, S. 161